Previous 10 | Next 10 |
Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 Study demonstrates clinical proof of mechanism with statistically significant increases in polycystin levels following RGLS4326 treatment in th...
Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 PR Newswire SAN DIEGO , June 21, 2021 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical ...
Gainers: Orphazyme (ORPH) +193%.Trxade Group (MEDS) +142%.Medley Management (MDLY) +61%.Sphere 3D (ANY) +54%.Yiren Digital (YRD) +25%.Orbsat Corp (OSAT) +22%.Alset EHome International (AEI) +22%.Xinyuan Real Estate (XIN) +21%.Support.com (SPRT) +20%.RH (RH) +14%.Losers: Aethlon...
Penny Stocks To Watch For June Trading penny stocks is something that millions of people do daily. But it’s isn’t something that everyone has been able to master. Best-known for their high-flying moves in price, the “land of cheap stocks” is more frequently c...
Regulus Therapeutics ([[RGLS]] -2.4%) is trading lower today adding to more than a fifth of the value it has lost over the past 30-day period.Today, the company announced detailed results from the first cohort of patients in an ongoing Phase 1b clinical trial of RGLS4326 for patient...
Regulus Therapeutics Announces Incremental Update of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program Data to Be Presented Today at the Oppenheimer Rare & Orphan Disease Summit PR Newswire SAN DIEGO , May 21, 2021 /PRNewswire/ -- Regulus T...
Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit Regulus Therapeutics to Present at the Oppenheimer Rare & Orphan Disease Summit PR Newswire SAN DIEGO , May 14, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nas...
Regulus Therapeutics Inc. (RGLS) Q1 2021 Earnings Conference Call May 13, 2021 05:00 PM ET Company Participants Cris Calsada - Chief Financial Officer Jay Hagan - President & Chief Executive Officer Denis Drygin - Chief Scientific Officer Conference Call Participants Shveta Dighe - Wedbus...
Regulus Therapeutics (RGLS): Q1 GAAP EPS of -$0.08 beats by $0.01.As of March 31, 2021, Regulus had $31.6 million in cash and cash equivalents.Press Release For further details see: Regulus Therapeutics EPS beats by $0.01
Regulus Therapeutics Reports First Quarter 2021 Financial Results and Recent Updates Regulus Therapeutics Demonstrates Target Engagement in First-Ever Study of RGLS4326 in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) Second Cohort Underway with Data Exp...
News, Short Squeeze, Breakout and More Instantly...
Regulus Therapeutics Inc. Company Name:
RGLS Stock Symbol:
NASDAQ Market:
Regulus Therapeutics Inc. Website:
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) PR Newswire Continued mechanistic dose resp...
Regulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® Indexes PR Newswire SAN DIEGO , June 4, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and devel...
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer PR Newswire SAN DIEGO , May 16, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of inn...